Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invesco Biotechnology & Genome ETF (NY:PBE)

76.12 -0.21 (-0.28%)
Official Closing Price Updated: 8:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Invesco Biotechnology & Genome ETF

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters
Via Stocktwits
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion
Via Stocktwits
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease
Via Stocktwits
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts. 
Via InvestorPlace
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
 
Via Benzinga
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
 
Via Benzinga
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
Biotech ETFs That Outperformed Last Week
Though the broad U.S. market saw a tumultuous ride last week with most of the sectors in red, biotechnology was the biggest gainer. 
Via Talk Markets
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
5 Top ETFs With Exposure To Biogen
Here is a look at five ETFs with large exposure to Biogen shares. 
Via Talk Markets
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
3 Biotech Stocks Wall Street Predicts Will Rally By 45% Or More
Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO​​​​​​​), BioDelivery Sciences (BDSI) and Champions Oncology (CSBR) gaining more... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.